Akums Drugs & Pharmaceuticals Ltd., a key player in India’s contract drug manufacturing space, has caught the attention of investors after global brokerage firm Citi reaffirmed its bullish stance. With a target price of Rs 700 per share, the stock could deliver a potential 36% upside from current levels. But does it justify a buy?
Stock Holding Steady Despite Market Volatility
Shares of Akums Drugs & Pharmaceuticals Ltd. were trading at Rs 516 per share on Thursday, reflecting a marginal dip of 0.2% from the previous day’s close. The company’s market capitalization stood at Rs 8,229.97 crore, solidifying its presence as a dominant contract development and manufacturing organization (CDMO) in the Indian pharma sector.
While broader market fluctuations have weighed on sentiment, Citi remains optimistic. The firm believes the company’s long-term growth potential outweighs short-term concerns, particularly given its latest contract wins and international expansion plans.
What’s Driving the 36% Upside?
A major catalyst for Citi’s bullish call is Akums’ recent 200-million-euro CDMO contract with a global pharmaceutical player. The company has already secured half of the deal’s value, boosting confidence in its execution capabilities.
- Akums is India’s largest domestic-focused CDMO and the second-largest overall.
- The company benefits from large-scale operations, strong manufacturing capabilities, and an expanding international footprint.
- API price corrections and weaker CDMO revenues in the past year created temporary headwinds, but Citi expects recovery in H1FY26E.
Further, Akums is aggressively expanding its production facilities in Hardwar and Baddi, setting the stage for a more prominent global presence. The company trades at 12x FY27E EBITDA, significantly below its closest competitor, which Citi values at 15x CDMO EBITDA and 10x non-CDMO EBITDA.
Financials: Short-Term Pain, Long-Term Gain?
Akums reported Q3 FY25 revenues of Rs 1,010 crore, down from Rs 1,083 crore in the same quarter last year. Net profit plunged to Rs 66 crore from Rs 195 crore in Q3 FY24, raising concerns about earnings stability.
However, the operating margin improved to 12% from 9%, indicating better cost management despite revenue declines. Key financial metrics include:
| Metric | Q3 FY25 | Q3 FY24 |
|---|---|---|
| Revenue (Rs Cr) | 1,010 | 1,083 |
| Net Profit (Rs Cr) | 66 | 195 |
| Operating Margin | 12% | 9% |
| ROE | 9.8% | N/A |
| ROCE | 7.5% | N/A |
Despite the dip in earnings, Citi believes that the upcoming recovery in CDMO revenues will drive a rebound in valuation.
Should Investors Buy?
Citi’s 36% upside target paints an optimistic picture. However, investors must weigh the short-term financial pressures against the company’s long-term growth strategy. The API pricing environment remains challenging, and near-term earnings volatility is a risk. Yet, Akums’ aggressive expansion, strong CDMO positioning, and valuation discount to peers make it a compelling stock to watch in the Indian pharma space.
One thing’s clear: the next few quarters will be crucial in determining whether Akums lives up to Citi’s expectations.
